Colorectal cancer (CRC) (BRAF m)

Patients diagnosed with Colorectal cancer (CRC) (BRAF m) generally have a poorer prognosis compared to those without such mutations.
Park et al. 2021b Future Oncology 17: 4221-4231

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling.
Kopetz et al. 2019 N Engl J Med 381: 1632-1643

BRAF V600E mutations are present in 8%–10% of patients with metastatic colorectal cancer (mCRC)
Johnson et al. 2018 The Oncologist 23: 128-134

…